Hyperthermic Extracorporeal Applied Tumor Therapy for Six Cycles for Recurrent Metastatic Peritoneal Serous Papillary Carcinoma

Roger A Vertrees; Joseph B Zwischenberger; Jan A Winetz

doi:10.7759/cureus.34100

Hyperthermic Extracorporeal Applied Tumor Therapy for Six Cycles for Recurrent Metastatic Peritoneal Serous Papillary Carcinoma

Cureus. 2023 Jan 23;15(1):e34100. doi: 10.7759/cureus.34100. eCollection 2023 Jan.

Authors

Roger A Vertrees¹, Joseph B Zwischenberger^{2

3}, Jan A Winetz⁴

Affiliations

¹ Pathology, ®Verthermia Acquisition, Inc., Henderson, USA.
² Surgery, ®Verthermia Acquisition, Inc., Henderson, USA.
³ Surgery, University of Kentucky, Lexington, USA.
⁴ Critical Care, ®Verthermia Acquisition, Inc., Henderson, USA.

Abstract

An elderly female with failed third-line peritoneal serous papillary carcinoma with metastasis (ovarian cancer) was treated by our proprietary method of whole-body hyperthermia-a recirculating extracorporeal circuit at 42°C for 120 minutes. She received six cycles, 28 days apart. Five index lesions were measured prior to and after each treatment. Results showed stable disease with reduced standard uptake volume. She then restarted six cycles of a previously failed chemotherapy, resulting in no evidence of disease for nine months; she survived for 27 months. Using our technology, the patient experienced an improvement in the quality of life and an increase in survival.

Keywords: extracorporeal technology; extracorporeal whole-body hyperthermia; hyperthermia; ovarian cancer; perfusion hyperthermia.

Publication types

Case Reports

Grants and funding

®Verthermia Acquisition Inc. has received money from private investors.